National Institute of Neurological Disorders and Stroke, Muscular Dystrophy Coordinating Committee Call for Committee Membership Nominations, 10777-10778 [2017-03018]
Download as PDF
<![CDATA[
Federal Register / Vol. 82, No. 30 / Wednesday, February 15, 2017 / Notices
FOR FURTHER INFORMATION CONTACT:
mstockstill on DSK3G9T082PROD with NOTICES
Licensing information and copies of the
patent applications listed below may be
obtained by communicating with the
indicated licensing contact at the
Technology Transfer and Intellectual
Property Office, National Institute of
Allergy and Infectious Diseases, 5601
Fishers Lane, Rockville, MD 20852; tel.
301–496–2644. A signed Confidential
Disclosure Agreement will be required
to receive copies of unpublished patent
applications.
SUPPLEMENTARY INFORMATION:
Technology description follows.
Single-Chain Antibodies Directed to
Norovirus GI.1 and GII.4 and Their Use
Description of Technology: Vaccines
and therapies to prevent and treat
Norovirus infections are not available,
despite the worldwide prevalence of
Norovirus infections. Outbreaks of
human gastroenteritis attributable to
Norovirus commonly occur in group
settings, such as hospitals, nursing
homes, schools, dormitories, cruise
ships and military barracks. This
application claims isolated VHH
monoclonal antibodies that specifically
bind to a Norovirus polypeptide. Llamaderived single chain antibody fragments
(also called VHH) are small,
recombinant monoclonal antibodies of
15 kDa (‘‘nanobodies’’) with several
advantages over conventional
antibodies. The antibodies that were
derived from llamas showed strong
neutralizing activity against Norovirus
in in vitro assays. These nanobodies
may have application as
immunoprophylaxis to protect
individuals from infections or as a
possible treatment for infected
individuals, or can be used to develop
a diagnostic for detection of norovirus
infections, and may be potentially
utilized in vaccine research.
This technology is available for
licensing for commercial development
in accordance with 35 U.S.C. 209 and 37
CFR part 404, as well as for further
development and evaluation under a
research collaboration.
Potential Commercial Applications:
• Therapeutics
• Diagnostics
• Vaccine research
Competitive Advantages:
• Ease of manufacture
• Potent neutralizing activity
• Potential cross-reactivity
• Low-cost therapeutics/
immunoprophylaxis
Development Stage:
• In vivo data assessment (animal)
Inventors: Lisbeth Kim Green (NIAID),
Karin Bok (NIAID), Stanislav
VerDate Sep<11>2014
18:44 Feb 14, 2017
Jkt 241001
Sosnovtsev (NIAID), Marina Bok (EM),
Pamela Aguilar (EM), Lorena
Garaicoechea (EM), and Viviana Parreno
(EM).
Publications: Garaicoechea L. et al.,
‘‘Llama nanoantibodies with therapeutic
potential against human norovirus
diarrhea,’’ PLoS One. 2015 Aug
12;10(8):e0133665. doi:10.1371/
journal.pone.0133665. eCollection 2015.
[PMID 26267898].
Intellectual Property: HHS Reference
No. E–136–2013/0—U.S. Provisional
Application No. 61/821,354, filed May
9, 2013; PCT Application No. PCT/
US2014/037520, filed May 9, 2014;
European Application No. 14727696.8,
filed May 9, 2014 (pending); U.S.
Application No. 14/889,774, filed
November 6, 2015 (pending); and
Argentine Application No.
20140101882, filed May 9, 2014
(pending).
Licensing Contact: Peter Soukas, J.D.,
301–594–8730; peter.soukas@nih.gov.
Collaborative Research Opportunity:
The National Institute of Allergy and
Infectious Diseases is seeking statements
of capability or interest from parties
interested in collaborative research to
further develop, evaluate or
commercialize for development of a
therapeutic, diagnostic or vaccine for
Norovirus infections. For collaboration
opportunities, please contact Peter
Soukas, J.D., 301–594–8730;
peter.soukas@nih.gov.
Dated: February 8, 2017.
Suzanne Frisbie,
Deputy Director, Technology Transfer and
Intellectual Property Office, National Institute
of Allergy and Infectious Diseases.
[FR Doc. 2017–03015 Filed 2–14–17; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Neurological
Disorders and Stroke, Muscular
Dystrophy Coordinating Committee
Call for Committee Membership
Nominations
The Office of the Secretary of
the Department of Health and Human
Services (HHS) is seeking nominations
for an individual to serve as a
nonfederal public member on the
Muscular Dystrophy Coordinating
Committee.
DATES: Nominations are due by 5 p.m.
EST on March 17, 2017.
ADDRESSES: Nominations must be sent
to Glen Nuckolls, Ph.D., by email to
nuckollg@ninds.nih.gov.
SUMMARY:
PO 00000
Frm 00044
Fmt 4703
Sfmt 4703
10777
Glen
Nuckolls, Ph.D., by email to nuckollg@
ninds.nih.gov.
SUPPLEMENTARY INFORMATION: The
Muscular Dystrophy Coordinating
Committee (MDCC) is a federal advisory
committee established in accordance
with the Muscular Dystrophy
Community Assistance, Research, and
Education Amendments of 2001 (MD–
CARE Act; Pub. L. 107–84). The MD–
CARE Act was reauthorized in 2008 by
Pub. L. 110–361, and again in 2014 by
Pub. L. 113–166. The MD–CARE Act
specifies that the committee
membership be composed of 2/3
governmental agency representatives
and 1/3 public members. We are seeking
nominations for four non-federal, public
members at this time, due to turnover of
committee membership. Nominations
will be accepted between February 17
and March 17, 2017.
Who is Eligible: Nominations are
encouraged for new or reappointment of
non-federal public members who can
provide the public and/or patient
perspectives to discussions of issues
considered by the Committee. Selfnominations and nominations of other
individuals are both permitted. Only
one nomination per individual is
required. Multiple nominations for the
same individual will not increase
likelihood of selection. Non-federal,
public members may be selected from
the pool of submitted nominations or
other sources as needed to meet
statutory requirements and to form a
balanced committee that represents the
diversity within the muscular dystrophy
communities. Nominations are
especially encouraged from leaders or
representatives of muscular dystrophy
research, advocacy, or service
organizations, individuals with
muscular dystrophy or their parents or
guardians. In accordance with White
House Office of Management and
Budget guidelines (FR Doc. 2014–
19140), federally-registered lobbyists are
not eligible.
Committee Composition: The
Department strives to ensure that the
membership of HHS Federal advisory
committees is fairly balanced in terms of
points of view represented and the
committee’s function. Every effort is
made to ensure that the views of all
genders, all ethnic and racial groups,
and people with disabilities are
represented on HHS Federal advisory
committees and, therefore, the
Department encourages nominations of
qualified candidates from these groups.
The Department also encourages
geographic diversity in the composition
of the Committee. Appointment to this
FOR FURTHER INFORMATION CONTACT:
E:\FR\FM\15FEN1.SGM
15FEN1
10778
Federal Register / Vol. 82, No. 30 / Wednesday, February 15, 2017 / Notices
Committee shall be made without
discrimination on the basis of age, race,
ethnicity, gender, sexual orientation,
disability, and cultural, religious, or
socioeconomic status. Requests for
reasonable accommodation to enable
participation on the Committee should
be indicated in the nomination
submission.
Member Terms: Non-Federal public
members of the Committee serve for a
term of 3 years, and may serve for an
unlimited number of terms if
reappointed. Members may serve after
the expiration of their terms, until their
successors have taken office.
Meetings and Travel: As specified by
Pub. L. 113–166, the MDCC ‘‘shall meet
no fewer than two times per calendar
year.’’ Travel expenses are provided for
non-federal public Committee members
to facilitate attendance at in-person
meetings. Members are expected to
make every effort to attend all full
committee meetings, twice per year,
either in person or via remote access.
Participation in relevant subcommittee,
working and planning group meetings,
and workshops, is also encouraged.
Submission Instructions and
Deadline: Nominations are due by 5
p.m. EST on March 17, 2017, and
should be sent to Glen Nuckolls, Ph.D.,
by email to nuckollg@ninds.nih.gov.
Nominations must include contact
information for the nominee, a current
curriculum vitae or resume of the
nominee and a paragraph describing the
qualifications of the person to represent
some portion(s) of the muscular
dystrophy research, advocacy and/or
patient care communities.
More information about the MDCC is
available at https://mdcc.nih.gov/.
Dated: February 10, 2017.
Walter J. Koroshetz,
Director, National Institute of Neurological
Disorders and Stroke, National Institutes of
Health.
[FR Doc. 2017–03018 Filed 2–14–17; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
mstockstill on DSK3G9T082PROD with NOTICES
National Institutes of Health
Center for Scientific Review; Amended
Notice of Meeting
Notice is hereby given of a change in
the meeting of the Genetic Variation and
Evolution Study Section, February 16,
2017, 08:00 a.m. to February 17, 2017,
07:00 p.m., Renaissance M Street Hotel,
1143 New Hampshire Avenue NW.,
Washington, DC 20037 which was
VerDate Sep<11>2014
18:44 Feb 14, 2017
Jkt 241001
published in the Federal Register on
January 23, 2017, 82 FR 7842.
The meeting will be held on 02/17/
2017 instead of 02/16/2017–02/17/2017.
The meeting time and location remains
the same. The meeting is closed to the
public.
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Dated: February 9, 2017.
David Clary,
Program Analyst, Office of Federal Advisory
Committee Policy.
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
[FR Doc. 2017–03013 Filed 2–14–17; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Biomedical
Imaging and Bioengineering; Notice of
Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Biomedical Imaging and Bioengineering
Special Emphasis Panel; K Award—R13
Review Meeting (2017/05).
Date: March 9, 2017.
Time: 10:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, Two
Democracy Plaza, Suite 920, 6707 Democracy
Boulevard, Bethesda, MD 20892 (Virtual
Meeting).
Contact Person: John K. Hayes, Ph.D.,
Scientific Review Officer, 6707 Democracy
Boulevard, Suite 959, Democracy Two,
Bethesda, MD 20892, (301) 451–3398,
hayesj@mail.nih.gov.
Dated: February 9, 2017.
David Clary,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2017–03012 Filed 2–14–17; 8:45 am]
BILLING CODE 4140–01–P
PO 00000
Frm 00045
Fmt 4703
Sfmt 4703
National Institutes of Health
National Institute of Allergy and
Infectious Diseases; Notice of Closed
Meeting
Name of Committee: Microbiology,
Infectious Diseases and AIDS Initial Review
Group; Microbiology and Infectious Diseases
B Subcommittee MID–B March 2017.
Date: March 6–7, 2017.
Time: 8:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Marriott Courtyard Gaithersburg
Washingtonian Center, 204 Boardwalk Place,
Gaithersburg, MD 20878.
Contact Person: Ellen S. Buczko, Ph.D.,
Scientific Review Officer, Scientific Review
Program, Division of Extramural Activities,
National Institutes of Health/NIAID, 6700B
Rockledge Drive, MSC 7616, Bethesda, MD
20892–7616, 301–451–2676, ebuczko1@
niaid.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.855, Allergy, Immunology,
and Transplantation Research; 93.856,
Microbiology and Infectious Diseases
Research, National Institutes of Health, HHS)
Dated: February 9, 2017.
Natasha M. Copeland,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2017–03014 Filed 2–14–17; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions;
Availability for Licensing
AGENCY:
National Institutes of Health,
HHS.
ACTION:
Notice.
The invention listed below is
owned by an agency of the U.S.
Government and is available for
SUMMARY:
E:\FR\FM\15FEN1.SGM
15FEN1
]]>Agencies
[Federal Register Volume 82, Number 30 (Wednesday, February 15, 2017)]
[Notices]
[Pages 10777-10778]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2017-03018]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Institute of Neurological Disorders and Stroke, Muscular
Dystrophy Coordinating Committee Call for Committee Membership
Nominations
SUMMARY: The Office of the Secretary of the Department of Health and
Human Services (HHS) is seeking nominations for an individual to serve
as a nonfederal public member on the Muscular Dystrophy Coordinating
Committee.
DATES: Nominations are due by 5 p.m. EST on March 17, 2017.
ADDRESSES: Nominations must be sent to Glen Nuckolls, Ph.D., by email
to nuckollg@ninds.nih.gov.
FOR FURTHER INFORMATION CONTACT: Glen Nuckolls, Ph.D., by email to
nuckollg@ninds.nih.gov.
SUPPLEMENTARY INFORMATION: The Muscular Dystrophy Coordinating
Committee (MDCC) is a federal advisory committee established in
accordance with the Muscular Dystrophy Community Assistance, Research,
and Education Amendments of 2001 (MD-CARE Act; Pub. L. 107-84). The MD-
CARE Act was reauthorized in 2008 by Pub. L. 110-361, and again in 2014
by Pub. L. 113-166. The MD-CARE Act specifies that the committee
membership be composed of 2/3 governmental agency representatives and
1/3 public members. We are seeking nominations for four non-federal,
public members at this time, due to turnover of committee membership.
Nominations will be accepted between February 17 and March 17, 2017.
Who is Eligible: Nominations are encouraged for new or
reappointment of non-federal public members who can provide the public
and/or patient perspectives to discussions of issues considered by the
Committee. Self-nominations and nominations of other individuals are
both permitted. Only one nomination per individual is required.
Multiple nominations for the same individual will not increase
likelihood of selection. Non-federal, public members may be selected
from the pool of submitted nominations or other sources as needed to
meet statutory requirements and to form a balanced committee that
represents the diversity within the muscular dystrophy communities.
Nominations are especially encouraged from leaders or representatives
of muscular dystrophy research, advocacy, or service organizations,
individuals with muscular dystrophy or their parents or guardians. In
accordance with White House Office of Management and Budget guidelines
(FR Doc. 2014- 19140), federally-registered lobbyists are not eligible.
Committee Composition: The Department strives to ensure that the
membership of HHS Federal advisory committees is fairly balanced in
terms of points of view represented and the committee's function. Every
effort is made to ensure that the views of all genders, all ethnic and
racial groups, and people with disabilities are represented on HHS
Federal advisory committees and, therefore, the Department encourages
nominations of qualified candidates from these groups. The Department
also encourages geographic diversity in the composition of the
Committee. Appointment to this
[[Page 10778]]
Committee shall be made without discrimination on the basis of age,
race, ethnicity, gender, sexual orientation, disability, and cultural,
religious, or socioeconomic status. Requests for reasonable
accommodation to enable participation on the Committee should be
indicated in the nomination submission.
Member Terms: Non-Federal public members of the Committee serve for
a term of 3 years, and may serve for an unlimited number of terms if
reappointed. Members may serve after the expiration of their terms,
until their successors have taken office.
Meetings and Travel: As specified by Pub. L. 113-166, the MDCC
``shall meet no fewer than two times per calendar year.'' Travel
expenses are provided for non-federal public Committee members to
facilitate attendance at in-person meetings. Members are expected to
make every effort to attend all full committee meetings, twice per
year, either in person or via remote access. Participation in relevant
subcommittee, working and planning group meetings, and workshops, is
also encouraged.
Submission Instructions and Deadline: Nominations are due by 5 p.m.
EST on March 17, 2017, and should be sent to Glen Nuckolls, Ph.D., by
email to nuckollg@ninds.nih.gov.
Nominations must include contact information for the nominee, a
current curriculum vitae or resume of the nominee and a paragraph
describing the qualifications of the person to represent some
portion(s) of the muscular dystrophy research, advocacy and/or patient
care communities.
More information about the MDCC is available at https://mdcc.nih.gov/.
Dated: February 10, 2017.
Walter J. Koroshetz,
Director, National Institute of Neurological Disorders and Stroke,
National Institutes of Health.
[FR Doc. 2017-03018 Filed 2-14-17; 8:45 am]
BILLING CODE 4140-01-P
